Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2016 02:30 ET | Source: Hansa Medical AB

Notice of Extraordinary General Meeting of Hansa Medical AB (publ)

The shareholders of Hansa Medical AB (publ) are summoned to attend the Extraordinary General Meeting on 21 November 2016, at 10:30 am CET at Hansa Medical’s offices on Scheelevägen 22, Lund,...
October 20, 2016 02:30 ET | Source: Hansa Medical AB

Hansa Medical föreslår riktad nyemission

· Styrelsen för Hansa Medical AB (publ) (”Hansa Medical” eller ”Bolaget”) föreslår en riktad nyemission av aktier om cirka 185 miljoner kronor. · Teckningskursen i emissionen föreslås uppgå till 70...
October 20, 2016 02:30 ET | Source: Hansa Medical AB

Kallelse till extra bolagsstämma i Hansa Medical AB (publ)

Hansa Medical AB (publ) kallar till extra bolagsstämma den 21 november 2016 kl. 10.30 i Hansa Medicals lokaler på Scheelevägen 22 i Lund. Aktieägarna i Hansa Medical AB (publ) kallas härmed till extra...
October 20, 2016 02:30 ET | Source: Hansa Medical AB

Hansa Medical proposes a directed share issue

· The board of directors of Hansa Medical AB (publ) (“Hansa Medical” or the “Company”) proposes a directed share issue of approximately SEK 185 million. · The subscription price for the issue is...
October 11, 2016 02:30 ET | Source: Hansa Medical AB

Första patienten behandlad med IdeS i fas II-studie i förvärvad Trombotisk Trombocytopen Purpura (TTP)

Hansa Medical AB (publ) meddelade idag att den första patienten har behandlats i en klinisk fas II-studie med IdeS i den akuta autoimmuna sjukdomen förvärvad Trombotisk Trombocytopen Purpura (TTP) vid...
October 11, 2016 02:30 ET | Source: Hansa Medical AB

First patient treated with IdeS in Phase II study in acquired Thrombotic Thrombocytopenic Purpura (TTP)

Hansa Medical AB (publ) today announced that the first patient has been recruited and treated in a Phase II clinical study with IdeS in the acute autoimmune disease acquired Thrombotic...
October 03, 2016 02:30 ET | Source: Hansa Medical AB

Första patienten behandlad i Hansa Medicals studie Highdes

Hansa Medical AB (publ) meddelade idag att den första patienten har behandlats med läkemedelskandidaten IdeS och därefter njurtransplanteras i multicenterstudien Highdes för desensitiseing av...
October 03, 2016 02:30 ET | Source: Hansa Medical AB

First patient treated in Hansa Medical’s Highdes-study

Hansa Medical AB (publ) today announced that the first patient has been treated and subsequently transplanted in the pivotal multicenter study Highdes using IdeS to desensitize highly sensitized...
August 23, 2016 02:30 ET | Source: Hansa Medical AB

Top line results from the Swedish ongoing Phase II study with IdeS in sensitized patients presented

Hansa Medical AB (publ) today announced that preliminary results of the Sweden based ongoing Phase II study of IdeS were presented today by Professor Gunnar Tufveson at the 26th International Congress...
August 23, 2016 02:30 ET | Source: Hansa Medical AB

Resultat från pågående svenska fas II-studien med IdeS i sensitiserade patienter presenterade

Hansa Medical AB (publ) meddelade idag att de preliminära resultaten från den pågående svenska fas II-studien med IdeS presenterades av professor Gunnar Tufveson vid 26th International Congress of the...